Nektar Therapeutics (NKTR)

Nektar Therapeutics' stock price has experienced significant fluctuations in the past six months. The stock surged approximately 150% on June 24, 2025, following positive results from its Phase 2b REZOLVE-AD study. On November 6, 2025, the stock rose 1.57% despite a net loss of $35.5 million in Q3 2025, as the company maintained a strong financial position. On December 16, 2025, the stock declined by 7.77% following the announcement of topline results from the Phase 2b REZOLVE-AA trial, where the primary endpoint narrowly missed statistical significance. On January 30, 2026, Nektar Therapeutics reported inducement grants under Nasdaq Listing Rule 5635(c)(4). As of February 5, 2026, the closing stock price was $35.12, and on February 6, 2026, it was $36.81.

As a clinical-stage biopharmaceutical company, Nektar Therapeutics' revenue is primarily generated from royalty payments and collaboration agreements rather than direct product sales. There is no discernible demand seasonality for Nektar Therapeutics' products and services at this time.

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies that selectively modulate the immune system for autoimmune and chronic inflammatory diseases. The company operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry, and utilizes its proprietary PEGylation and polymer conjugate technology platforms to engineer drug candidates. Nektar's lead product candidate is rezpegaldesleukin, which is being evaluated in Phase 2b clinical trials for atopic dermatitis and alopecia areata, and in a Phase 2 clinical trial for Type 1 diabetes mellitus. The company's pipeline also includes preclinical bivalent tumor necrosis factor receptor type II antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor protein, NKTR-422. Nektar, in collaboration with various partners, is evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. The company's revenue is primarily derived from royalty payments rather than direct product sales.

Nektar Therapeutics is headquartered in San Francisco, California. The company's clinical development efforts have a global reach, with its Phase 2b REZOLVE-AD study for atopic dermatitis enrolling patients across approximately 110 global sites, primarily in Europe.

Nektar Therapeutics' brand reputation has shifted over the past year, driven by clinical trial outcomes. Positive results from the Phase 2b REZOLVE-AD study significantly boosted the company's standing, leading to a substantial increase in its stock price. The rezpegaldesleukin data were referenced in the background documents from the Nobel Committee for Physiology or Medicine. However, the Phase 2b REZOLVE-AA trial results presented a mixed picture, with the primary endpoint narrowly missing statistical significance, leading to a decline in stock price. Overall, Nektar is viewed as a "comeback story" and a "growth play" in the biotech sector, rebuilding its reputation around its focused immunology pipeline.

Nektar Therapeutics has a diverse ownership structure, including institutional, retail, and individual investors. Approximately 50.45% of the company's stock is owned by Institutional Investors, 5.13% by Insiders, and 44.42% by Public Companies and Individual Investors. Major institutional shareholders include Bvf Inc/il, Vanguard Group Inc, Morgan Stanley, Susquehanna International Group, Llp, Farallon Capital Management Llc, BlackRock, Inc., Millennium Management Llc, Two Sigma Investments, Lp, and Nantahala Capital Management, LLC.